MedPath

The Comparisons of One-stage Stone Removal in Mild and Moderate Cholangitis

Not Applicable
Completed
Conditions
Cholangitis; Choledocholithiasis
Interventions
Behavioral: One stage treatment for mild and moderate cholangitis with choledocholithiasis
Registration Number
NCT03754491
Lead Sponsor
Chang Gung Memorial Hospital
Brief Summary

In expert comment, performing the sphincterotomy for choledocholithiasis with acute cholangitis may increase bleeding and pancreatitis risks (from 2% to 10%). Therefore, investigators often perform biliary drainage in acute stage, and arrange 2nd session ERCP for stone removal later. However, in the recent study, single-stage endoscopic treatment may be still effective (stone removal rate 90%) and safe for mild to moderate acute cholangitis associated with choledocholithiasis. Investigators will carry out a prospective trial to analyze one-stage retrograde endoscopic common bile duct stone removal in mild and moderate cholangitis with choledocholithiasis to determine the safety, successful rate, and complications in these two groups.

Detailed Description

Investigators will enroll 204 naïve papilla with a body temperature ≥37 °C who was diagnosed with mild to moderate cholangitis associated with choledocholithiasis. The method of one-stage: performing the stone removal at the first session of ERCP. The pancreas duct stent will be placed for preventing post ERCP pancreatitis (PEP) if necessary. The indomethacin 100mg anal route will be administered for all patients without allergy history. All participants will receive the empiric antibiotics treatment for cholangitis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
196
Inclusion Criteria
  • naïve papilla with a body temperature ≥37 °C who was diagnosed with mild to moderate cholangitis associated with choledocholithiasis.
Exclusion Criteria
  • procedural failure requiring an anatomy-modifying procedure, such as a Billroth II subtotal gastrectomy or R-en-Y gastrojejunostomy ;
  • stenosis of the pyloric ring ;
  • tumor-related obstruction;
  • failure to locate the papilla ;
  • active peptic ulcer bleeding ;
  • intolerance due to inadequate sedation
  • CBD sludge;
  • non-naïve papilla in ERCP

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
One stage stone removal in mild cholangitisOne stage treatment for mild and moderate cholangitis with choledocholithiasisone-stage stone removal at the first session of ERCP in mild cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
One stage stone removal in moderate cholangitisOne stage treatment for mild and moderate cholangitis with choledocholithiasisone-stage stone removal at the first session of ERCP in moderate cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
Primary Outcome Measures
NameTimeMethod
Post ERCP pancreatitisAfter ERCP, an average of 7 days

Serum amylase \> 3 times of (115 IU/L) with clinical abdominal pain

Bowel perforationAfter ERCP, an average of 7 days

Participants with sign of bowel perforation after ERCP

Papillary bleedingAfter ERCP, an average of 7 days

Participants with papillary bleeding after ERCP

Success rate of stone removalan average of 14 days.

Complete bile duct stone clearance

Cost of hospitalizationFrom emergent department to the timing of being discharged, and an average of 30 days

Total cost in two individual groups in hospitalization.

Secondary Outcome Measures
NameTimeMethod
Mortalityan average of 30 days

Mortality during and after discharged

Trial Locations

Locations (1)

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath